PTRF CRISPR/Cas9 KO Plasmid (h): sc-404669
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PTRF CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PTRF genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PTRF Antibody (4a): sc-517589
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PTRF CRISPR/Cas9 KO Plasmid (h) | sc-404669 | 20 µg | $397.00 |
Overview
CAVIN1 encodes polymerase I and transcript release factor (PTRF/cavin-1), a core structural component of caveolae that cooperates with caveolins to stabilize flask-shaped plasma membrane invaginations. PTRF supports caveolae biogenesis and dynamics, contributing to lipid homeostasis, endocytosis, and mechanoprotection, and it influences signal transduction pathways organized at the cell surface. Through its roles in membrane organization and trafficking, PTRF can modulate receptor availability and downstream signaling responses to mechanical and metabolic cues. Dysregulation of CAVIN1/PTRF has been associated with altered caveolar function in muscle and adipose biology and has been studied in contexts including lipodystrophy-related phenotypes and tumor cell behavior.
PTRF CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CAVIN1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CAVIN1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CAVIN1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PTRF protein expression.
This CRISPR knockout system enables efficient generation of CAVIN1-deficient cell models for investigation of PTRF signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CAVIN1 exon(s) critical for PTRF function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CAVIN1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PTRF CRISPR/Cas9 KO Plasmid (h) and PTRF CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CAVIN1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PTRF HDR Plasmid (h) and PTRF HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CAVIN1 homology arms to support homology-directed repair at defined CAVIN1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.